Activity from announced rounds
Carma Fund is the investment brand named in the Allogenetics and Exciva financing histories.
Allogenetics develops an ex vivo gene-therapy approach that modifies donor organs before transplantation to reduce rejection. Exciva develops therapies for behavioral symptoms associated with Alzheimer’s disease. The covered announcements use the unnumbered brand; they do not identify a particular fund vintage.
Allogenetics is developing a one-time ex vivo gene therapy that modifies donor organs before transplantation, aiming to reduce immune rejection without suppressing the recipient’s immune system. Its lead ALG-115 program is advancing through preclinical and IND-enabling work for lung transplantation.